Skip to main content
Erschienen in: gynäkologie + geburtshilfe 4/2018

03.07.2018 | Alopezie | Fortbildung

Ein Haarausfall mit vielen Facetten

Alopecia androgenetica der Frau

verfasst von: PD Dr. med. Gerhard Lutz

Erschienen in: gynäkologie + geburtshilfe | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aufgrund der Vielgestaltigkeit der Ausfallsmuster und der zahlreichen möglichen Ursachen betrachten viele Ärzte Haarausfall als crux medicorum. Doch das Problem ist beherrschbar. Wichtig ist, zu unterscheiden, ob der Haarausfall durch eine bestehende Hyperandrogenämie oder nur durch eine erhöhte Sensitivität der Haarfollikel gegenüber den Androgenen verursacht wird.
Literatur
1.
Zurück zum Zitat Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97: 247–54CrossRefPubMed Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97: 247–54CrossRefPubMed
2.
Zurück zum Zitat Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol 2017; 11: 7–12CrossRefPubMedPubMedCentral Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol 2017; 11: 7–12CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Harries M et al. Towards a consensus on how to diagnose and quantify female pattern hair loss — The ‚Female Pattern Hair Loss Severity Index (FPHL-SI)‘. J Eur Acad Dermatol Venereol 2016; 30: 667–76CrossRefPubMed Harries M et al. Towards a consensus on how to diagnose and quantify female pattern hair loss — The ‚Female Pattern Hair Loss Severity Index (FPHL-SI)‘. J Eur Acad Dermatol Venereol 2016; 30: 667–76CrossRefPubMed
4.
Zurück zum Zitat Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951; 53: 708–28CrossRefPubMed Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951; 53: 708–28CrossRefPubMed
5.
Zurück zum Zitat Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359–65CrossRefPubMed Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68: 1359–65CrossRefPubMed
7.
Zurück zum Zitat Whigley et al. Natural mutagenesis study of the human steroid 5-alpha-reductase 2 isozyme. Biochemistry 1994; 33: 1265–70CrossRef Whigley et al. Natural mutagenesis study of the human steroid 5-alpha-reductase 2 isozyme. Biochemistry 1994; 33: 1265–70CrossRef
8.
Zurück zum Zitat Lutz G. Alopecia androgenetica des Mannes — Status Quo. Der Deutsche Dermatologe 2002; 5: 324–33 Lutz G. Alopecia androgenetica des Mannes — Status Quo. Der Deutsche Dermatologe 2002; 5: 324–33
9.
Zurück zum Zitat Sawaya ME, Price VH. Different levels of 5-alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296–300CrossRefPubMed Sawaya ME, Price VH. Different levels of 5-alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296–300CrossRefPubMed
10.
Zurück zum Zitat Redler S et al. Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified. Exp Dermatol 2012; 21: 390–3CrossRefPubMed Redler S et al. Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified. Exp Dermatol 2012; 21: 390–3CrossRefPubMed
11.
Zurück zum Zitat Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol 2006; 155: 926–30CrossRefPubMed Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol 2006; 155: 926–30CrossRefPubMed
12.
13.
Zurück zum Zitat Adachi K, Kano M. Adenyl cyclase in human hair follicles. Its inhibition by dihydrotestosterone. Biochem Biophys Res Commun 1970; 41: 884–90CrossRefPubMed Adachi K, Kano M. Adenyl cyclase in human hair follicles. Its inhibition by dihydrotestosterone. Biochem Biophys Res Commun 1970; 41: 884–90CrossRefPubMed
14.
Zurück zum Zitat Riedel-Baima B, Riedel A. Female pattern hair loss may be triggered by low oestrogen to androgen ratio. Endocr Regul 2008; 42: 13–6PubMed Riedel-Baima B, Riedel A. Female pattern hair loss may be triggered by low oestrogen to androgen ratio. Endocr Regul 2008; 42: 13–6PubMed
15.
Zurück zum Zitat Skalnaya MG, Tkachev VP. Trace elements content and hormonal profiles in women with androgenetic alopecia. J Trace Elem Med Biol 2011; 25 Suppl 1: 50–3CrossRef Skalnaya MG, Tkachev VP. Trace elements content and hormonal profiles in women with androgenetic alopecia. J Trace Elem Med Biol 2011; 25 Suppl 1: 50–3CrossRef
16.
Zurück zum Zitat Urysiak-Czubatka I et al. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Postepy Dermatol Alergol 2014; 31: 207–15CrossRefPubMedPubMedCentral Urysiak-Czubatka I et al. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Postepy Dermatol Alergol 2014; 31: 207–15CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lutz G. Drug- induced hair loss. In: Dyall-Smith D, Marks R (eds.), Dermatology at the Millenium. The Proceedings of the 19th World Congress of Dermatology, Sydney, Australia, June 15–20, The Parthenon Publishing Group Ltd, New York, Carnforth 1999; 706–10 Lutz G. Drug- induced hair loss. In: Dyall-Smith D, Marks R (eds.), Dermatology at the Millenium. The Proceedings of the 19th World Congress of Dermatology, Sydney, Australia, June 15–20, The Parthenon Publishing Group Ltd, New York, Carnforth 1999; 706–10
19.
20.
Zurück zum Zitat Hillmer AM et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005; 77: 140–8CrossRefPubMedPubMedCentral Hillmer AM et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005; 77: 140–8CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Brent JR et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008; 40: 1282–4CrossRef Brent JR et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet 2008; 40: 1282–4CrossRef
22.
Zurück zum Zitat Brockschmidt FF et al. Six novel susceptibility Loci for early-onset androgenetic alopecia and their unexpected association with common diseases. Fine mapping of the human AR/EDA2R locus in androgenetic alopecia. PLoS Genet 2012; May; 8(5): e1002746CrossRefPubMedPubMedCentral Brockschmidt FF et al. Six novel susceptibility Loci for early-onset androgenetic alopecia and their unexpected association with common diseases. Fine mapping of the human AR/EDA2R locus in androgenetic alopecia. PLoS Genet 2012; May; 8(5): e1002746CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Redler S et al. Investigation of variants of the aromatase gene (CYP19A1) in female pattern hair loss. Br J Dermatol 2011; 165: 703–5CrossRefPubMed Redler S et al. Investigation of variants of the aromatase gene (CYP19A1) in female pattern hair loss. Br J Dermatol 2011; 165: 703–5CrossRefPubMed
24.
Zurück zum Zitat Redler S et al. Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in women with female pattern hair loss. Br J Dermatol 2012; 166: 1314–8CrossRefPubMed Redler S et al. Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in women with female pattern hair loss. Br J Dermatol 2012; 166: 1314–8CrossRefPubMed
25.
Zurück zum Zitat Redler S et al. Investigation of six novel susceptibility loci for male androgenetic alopecia in women with female pattern hair loss. J Dermatol Sci 2013; 72: 186–8CrossRefPubMed Redler S et al. Investigation of six novel susceptibility loci for male androgenetic alopecia in women with female pattern hair loss. J Dermatol Sci 2013; 72: 186–8CrossRefPubMed
26.
Zurück zum Zitat Yip L et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009; 161: 289–94CrossRefPubMed Yip L et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol 2009; 161: 289–94CrossRefPubMed
27.
Zurück zum Zitat Mahmoudi H et al. Selected variants of the melanocortin 4 receptor gene (MC4R) do not confer susceptibility to female pattern hair Loss. Arch Dermatol Res 2013; 305: 249–53CrossRefPubMed Mahmoudi H et al. Selected variants of the melanocortin 4 receptor gene (MC4R) do not confer susceptibility to female pattern hair Loss. Arch Dermatol Res 2013; 305: 249–53CrossRefPubMed
28.
Zurück zum Zitat Yip L et al. (2012) Association analysis of estrogen receptor beta gene (ESR2) polymorphism with female pattern hair loss. Br J Dermatol 2012; 166: 1131–4CrossRefPubMed Yip L et al. (2012) Association analysis of estrogen receptor beta gene (ESR2) polymorphism with female pattern hair loss. Br J Dermatol 2012; 166: 1131–4CrossRefPubMed
29.
Zurück zum Zitat Lutz G. Das Trichogramm — Indikation, Durchführung und Interpretation. Der Deutsche Dermatologe 2001; 4: 254–61 Lutz G. Das Trichogramm — Indikation, Durchführung und Interpretation. Der Deutsche Dermatologe 2001; 4: 254–61
30.
Zurück zum Zitat Hoffmann R. TrichoScan: Combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol 2001; 11: 362–8PubMed Hoffmann R. TrichoScan: Combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol 2001; 11: 362–8PubMed
31.
32.
Zurück zum Zitat Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14: 713–21CrossRefPubMed Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14: 713–21CrossRefPubMed
33.
Zurück zum Zitat Blumeyer A et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6: 1–57CrossRef Blumeyer A et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6: 1–57CrossRef
34.
Zurück zum Zitat Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77: 136–41CrossRefPubMed Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77: 136–41CrossRefPubMed
35.
Zurück zum Zitat Lachgar S et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermaltol 1998; 138: 407–11CrossRef Lachgar S et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermaltol 1998; 138: 407–11CrossRef
36.
Zurück zum Zitat Blume-Peytavi U et al. Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study. J Drugs Dermatol 2016; 15: 883–9PubMed Blume-Peytavi U et al. Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study. J Drugs Dermatol 2016; 15: 883–9PubMed
37.
Zurück zum Zitat Bergfeld W et al. A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss. J Drugs Dermatol 2016; 15: 874–81PubMed Bergfeld W et al. A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss. J Drugs Dermatol 2016; 15: 874–81PubMed
38.
Zurück zum Zitat Price VH et al. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41: 717–21CrossRefPubMed Price VH et al. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41: 717–21CrossRefPubMed
39.
Zurück zum Zitat Mc Coy et al. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 2016; 30: 1153–5 Mc Coy et al. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 2016; 30: 1153–5
40.
Zurück zum Zitat Orfanos CE, Vogels L. Lokaltherapie der Alopecia androgenetica mit 17 α-Estradiol-Östradiol. Dermatologica 1980; 161: 124–32CrossRefPubMed Orfanos CE, Vogels L. Lokaltherapie der Alopecia androgenetica mit 17 α-Estradiol-Östradiol. Dermatologica 1980; 161: 124–32CrossRefPubMed
41.
Zurück zum Zitat Wozel G et al. Alfatradiol (0,025%) — Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern. Akt Dermatol 2005; 31: 549–52CrossRef Wozel G et al. Alfatradiol (0,025%) — Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern. Akt Dermatol 2005; 31: 549–52CrossRef
42.
Zurück zum Zitat Kim HJ et al. The Efficacy and Savety of 17 α-Estradiol (Ell-Cranell®)alpha 0,025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comporative, Phase IV Study. Ann Dermatol 2012; 24: 295–305CrossRefPubMedPubMedCentral Kim HJ et al. The Efficacy and Savety of 17 α-Estradiol (Ell-Cranell®)alpha 0,025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comporative, Phase IV Study. Ann Dermatol 2012; 24: 295–305CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Schriefers H et al. Hemmung des Testosteronstoffwechsel durch 17 α-Estradiol in Rattenleberschnitten. Arzneimittelforschung/Drug Res 1991; 41: 1186–9 Schriefers H et al. Hemmung des Testosteronstoffwechsel durch 17 α-Estradiol in Rattenleberschnitten. Arzneimittelforschung/Drug Res 1991; 41: 1186–9
44.
Zurück zum Zitat Hoffmann R et al. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol 2002; 11: 376–80CrossRefPubMed Hoffmann R et al. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol 2002; 11: 376–80CrossRefPubMed
45.
Zurück zum Zitat Georgala S et al. Topical Estrogen Therapy for Androgenetic Alopecia in Menopausal Females. Dermatology 2004; 208: 178–9CrossRefPubMed Georgala S et al. Topical Estrogen Therapy for Androgenetic Alopecia in Menopausal Females. Dermatology 2004; 208: 178–9CrossRefPubMed
46.
Zurück zum Zitat Abadjieva TI. Treatment of androgenetic alopecia in females in reproductive age with topical estradiolbenzoate, prednisolon and salicylic acid. Folia Med (Plovdiv) 2000; 42: 26–9 Abadjieva TI. Treatment of androgenetic alopecia in females in reproductive age with topical estradiolbenzoate, prednisolon and salicylic acid. Folia Med (Plovdiv) 2000; 42: 26–9
47.
Zurück zum Zitat Emons G et al. Postmenopausal bleeding following the application of an estrogen-containing hair lotion — concomitant endocrine changes. Geburtshilfe Frauenheilkd 1984; 460–2 Emons G et al. Postmenopausal bleeding following the application of an estrogen-containing hair lotion — concomitant endocrine changes. Geburtshilfe Frauenheilkd 1984; 460–2
48.
Zurück zum Zitat Choe SJ et al. Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation. Ann Dermatol 2017; 29: 276–82CrossRefPubMedPubMedCentral Choe SJ et al. Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation. Ann Dermatol 2017; 29: 276–82CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Gassmueller J et al. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol 2008; 158:109–15PubMed Gassmueller J et al. Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies. Br J Dermatol 2008; 158:109–15PubMed
50.
Zurück zum Zitat Emer J et al. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. Drugs Dermatol 2011; 10: 795–8 Emer J et al. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. Drugs Dermatol 2011; 10: 795–8
52.
Zurück zum Zitat Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg 2010; 36: 1361–71CrossRefPubMed Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg 2010; 36: 1361–71CrossRefPubMed
53.
Zurück zum Zitat Wester ST et al. Eyelash growth from application of bimatoprost in gel suspension to the base of the yelashes. Ophthalmology 2010; 117: 1024–31CrossRefPubMedPubMedCentral Wester ST et al. Eyelash growth from application of bimatoprost in gel suspension to the base of the yelashes. Ophthalmology 2010; 117: 1024–31CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Legro RS et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. In: The Journal of clinical endocrinology and metabolism. 2013, Bd 98, 12: 4565–92CrossRef Legro RS et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. In: The Journal of clinical endocrinology and metabolism. 2013, Bd 98, 12: 4565–92CrossRef
55.
Zurück zum Zitat Dadachanji R et al. Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology. Genet Res Int 2018; 2018: 7624932PubMedPubMedCentral Dadachanji R et al. Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology. Genet Res Int 2018; 2018: 7624932PubMedPubMedCentral
56.
Zurück zum Zitat Orfanos CE et al. „The SAHA syndrome“. Horm Res 2000; 54: 251–8PubMed Orfanos CE et al. „The SAHA syndrome“. Horm Res 2000; 54: 251–8PubMed
57.
Zurück zum Zitat Simard J et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986; 44: 261–70CrossRefPubMed Simard J et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986; 44: 261–70CrossRefPubMed
58.
Zurück zum Zitat Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79: 91–5CrossRefPubMed Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79: 91–5CrossRefPubMed
59.
Zurück zum Zitat Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australas J Dermatol 2011; 52: 132–34CrossRefPubMed Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australas J Dermatol 2011; 52: 132–34CrossRefPubMed
60.
Zurück zum Zitat Paradisi R et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011; 45: 469–75CrossRefPubMed Paradisi R et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011; 45: 469–75CrossRefPubMed
61.
Zurück zum Zitat Spinucci G, Pasquali R. Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia? Clin Ter 1996; 147: 305–15PubMed Spinucci G, Pasquali R. Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia? Clin Ter 1996; 147: 305–15PubMed
62.
Zurück zum Zitat Trueb RM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004; 209: 202–7CrossRefPubMed Trueb RM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004; 209: 202–7CrossRefPubMed
63.
Zurück zum Zitat Iorizzo M et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142: 298–302CrossRefPubMed Iorizzo M et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142: 298–302CrossRefPubMed
65.
Zurück zum Zitat Price VH et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768–76.CrossRefPubMed Price VH et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768–76.CrossRefPubMed
66.
Zurück zum Zitat Lee SW et al. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol 2018; 17: 457–63PubMed Lee SW et al. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. J Drugs Dermatol 2018; 17: 457–63PubMed
67.
Zurück zum Zitat Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005; 4: 637–40.PubMed Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005; 4: 637–40.PubMed
68.
Zurück zum Zitat Moftah N et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol 2013; 27: 686–93CrossRefPubMed Moftah N et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol 2013; 27: 686–93CrossRefPubMed
69.
Zurück zum Zitat Wolff H et al. Diagnostik und Therapie von Haar- und Kopfhauterkrankungen. Dtsch Arztebl 2016; 113: 377–86. Wolff H et al. Diagnostik und Therapie von Haar- und Kopfhauterkrankungen. Dtsch Arztebl 2016; 113: 377–86.
70.
Zurück zum Zitat Seale LR et al. Side Effects Related to 5α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review. J Drugs Dermatol 2016; 15: 414–9PubMed Seale LR et al. Side Effects Related to 5α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review. J Drugs Dermatol 2016; 15: 414–9PubMed
71.
Zurück zum Zitat Roque LV et al. Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia. Skin Pharmacol Physiol 2017; 30: 197–204CrossRefPubMed Roque LV et al. Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia. Skin Pharmacol Physiol 2017; 30: 197–204CrossRefPubMed
72.
Zurück zum Zitat Vexiau P et al. Effects of minoxidil 2 % vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12 month randomized trial. Br J Dermatol 2002; 146: 992–9CrossRefPubMed Vexiau P et al. Effects of minoxidil 2 % vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12 month randomized trial. Br J Dermatol 2002; 146: 992–9CrossRefPubMed
74.
Zurück zum Zitat Conrad F et al. Substantial sex-dependent differences in the response of human scalp hair follicles to estrogen stimulation in vitro advocate gender-tailored management of female versus male pattern balding. J Investig Dermatol Symp Proc 2005; 10: 243–6.CrossRefPubMed Conrad F et al. Substantial sex-dependent differences in the response of human scalp hair follicles to estrogen stimulation in vitro advocate gender-tailored management of female versus male pattern balding. J Investig Dermatol Symp Proc 2005; 10: 243–6.CrossRefPubMed
75.
76.
Zurück zum Zitat Mirmirani P. Hormonal changes in menopause: do they contribute to a ‚midlife hair crisis‘ in women? Br J Dermatol 2011; 165 Suppl 3: 7–11CrossRefPubMed Mirmirani P. Hormonal changes in menopause: do they contribute to a ‚midlife hair crisis‘ in women? Br J Dermatol 2011; 165 Suppl 3: 7–11CrossRefPubMed
77.
Zurück zum Zitat Adenuga P et al. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy. Am Acad Dermatol 2012; 67: 121–3CrossRef Adenuga P et al. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy. Am Acad Dermatol 2012; 67: 121–3CrossRef
78.
Zurück zum Zitat Gabrilove JL, Luria M. Persistent gynecomastia resulting from scalp inuction of estradiol: a model for persisting gynecomastia. Arch Dermatol 1978; 114: 1672–3CrossRefPubMed Gabrilove JL, Luria M. Persistent gynecomastia resulting from scalp inuction of estradiol: a model for persisting gynecomastia. Arch Dermatol 1978; 114: 1672–3CrossRefPubMed
79.
Zurück zum Zitat Orfanos CE, Wüstner H. Penetration and side effects of local estrogen application in alopecia androgenetica. Hautarzt 1975; 26:367–9PubMed Orfanos CE, Wüstner H. Penetration and side effects of local estrogen application in alopecia androgenetica. Hautarzt 1975; 26:367–9PubMed
80.
Zurück zum Zitat Robbins C et al. What women want — quantifying the perception of hair amount: an analysis of hair diameter and density changes with age in caucasian women. Br J Dermatol 2012; 167: 324–32CrossRef Robbins C et al. What women want — quantifying the perception of hair amount: an analysis of hair diameter and density changes with age in caucasian women. Br J Dermatol 2012; 167: 324–32CrossRef
81.
Zurück zum Zitat Check JH, Cohen R. An update on the treatment of female alopecia and the introduction of a potential novel therapy. Clin Exp Obstet Gynecol 2015; 42: 411–5PubMed Check JH, Cohen R. An update on the treatment of female alopecia and the introduction of a potential novel therapy. Clin Exp Obstet Gynecol 2015; 42: 411–5PubMed
82.
83.
Zurück zum Zitat Guida M et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. J Womens Health Int 2010; 2: 279–90 Guida M et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. J Womens Health Int 2010; 2: 279–90
84.
Zurück zum Zitat Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a patter distribution. Arch Dermatol 1994; 130: 770–4CrossRefPubMed Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a patter distribution. Arch Dermatol 1994; 130: 770–4CrossRefPubMed
85.
Zurück zum Zitat Kossard S et al. Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. J Am Acad Dermatol 1997; 36: 59–66CrossRefPubMed Kossard S et al. Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. J Am Acad Dermatol 1997; 36: 59–66CrossRefPubMed
86.
Zurück zum Zitat Lutz G, Löser C. Primäre vernarbende Alopezien. Der Deutsche Dermatologe 2015; 4: 294–300CrossRef Lutz G, Löser C. Primäre vernarbende Alopezien. Der Deutsche Dermatologe 2015; 4: 294–300CrossRef
87.
Zurück zum Zitat Kanti V et al. Vernarbende Alopezien. J Dtsch Dermatol Ges 2018; 4: 435–61 Kanti V et al. Vernarbende Alopezien. J Dtsch Dermatol Ges 2018; 4: 435–61
88.
Zurück zum Zitat Olsen EA et al. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol 2010; 63: 991–9CrossRefPubMed Olsen EA et al. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol 2010; 63: 991–9CrossRefPubMed
89.
Zurück zum Zitat Lutz G. Nutritive Haarwachstumsförderung mit Spurenelementen, Vitaminen und sekundären Pflanzenbegleitstoffen bei Frauen. Akt Dermatol 2012; 38: 199–205CrossRef Lutz G. Nutritive Haarwachstumsförderung mit Spurenelementen, Vitaminen und sekundären Pflanzenbegleitstoffen bei Frauen. Akt Dermatol 2012; 38: 199–205CrossRef
90.
Zurück zum Zitat Gerkowicz A et al. The Role of Vitamin D in Non-Scarring Alopecia. Int J Mol Sci 2017; Dec 7; 18(12). pii: E2653CrossRefPubMed Gerkowicz A et al. The Role of Vitamin D in Non-Scarring Alopecia. Int J Mol Sci 2017; Dec 7; 18(12). pii: E2653CrossRefPubMed
91.
Zurück zum Zitat Conic RRZ et al. Vitamin D Status in Scarring and Non-Scarring Alopecia. J Am Acad Dermatol 2018 Apr 21. pii: S0190-9622(18)30631-5 Conic RRZ et al. Vitamin D Status in Scarring and Non-Scarring Alopecia. J Am Acad Dermatol 2018 Apr 21. pii: S0190-9622(18)30631-5
92.
Zurück zum Zitat Halsner U. Eigenhaartransplantion — Punch Technik. Kosmet Med 2000; 21: 16–8 Halsner U. Eigenhaartransplantion — Punch Technik. Kosmet Med 2000; 21: 16–8
93.
Zurück zum Zitat Neidel G, Leonhardt K. Haartransplantation bei Frauen — eine normale Prozedur? derm 2004; 10: 1–6 Neidel G, Leonhardt K. Haartransplantation bei Frauen — eine normale Prozedur? derm 2004; 10: 1–6
94.
95.
Zurück zum Zitat Sinclair R et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol 2011; 165 Suppl 3: 12–8CrossRefPubMed Sinclair R et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol 2011; 165 Suppl 3: 12–8CrossRefPubMed
Metadaten
Titel
Ein Haarausfall mit vielen Facetten
Alopecia androgenetica der Frau
verfasst von
PD Dr. med. Gerhard Lutz
Publikationsdatum
03.07.2018
Verlag
Springer Medizin
Erschienen in
gynäkologie + geburtshilfe / Ausgabe 4/2018
Print ISSN: 1439-3557
Elektronische ISSN: 2196-6435
DOI
https://doi.org/10.1007/s15013-018-1472-4

Weitere Artikel der Ausgabe 4/2018

gynäkologie + geburtshilfe 4/2018 Zur Ausgabe

Die letzte Seite

Form aus Farbe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.